Drozitumab

N/A

Report date: 2022/07/04 19:38:02

Base Information

Drug NameDrozitumab
Drug Alias NameApomab,Apomab 7.3RG-7425R-7425PRO-95780
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionTumor necrosis factor receptor superfamily member 10B agonists
TargetsTumor necrosis factor receptor superfamily member 10B
Therapy Area/IndicationsCarcinoma, Non-Small-Cell LungColorectal NeoplasmsChondrosarcoma +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesAustralia
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesGenentech Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesGenentech Inc
Active IndicationsN/A
Inactive IndicationsCarcinoma, Non-Small-Cell LungColorectal NeoplasmsChondrosarcoma +[4] 

Other Information

ATC CodeN/A
Related LinksWikipediaKEGG